BRAF and non-small cell lung carcinoma: MAPK pathway is estimated to be deregulated in almost 50% of human malignancies, activating mutation of BRAF in 5–10% of cancers, especially hairy cell leukemia, melanoma, colorectal cancer, papillary thyroid cancer, non-small cell lung cancer (NSCLC), and ovarian cancer [100].